Deep in
dermatology

Part of the international Biofrontera Group, Biofrontera UK is a specialist dermatology company, innovating to develop new scientific solutions to assist in the management of dermatological conditions, from skin lesions and cancer to dermatitis, psoriasis and beyond.

Discover more
600+ patients in phase III trials1

We are committed to advancing dermatological care in the UK,
via scientific innovation, as well as considered collaboration with healthcare professionals, NHS organisations and industry partners.

Over two decades of experience developing dermatology solutions

With extensive experience spanning more than two decades, our Biofrontera UK portfolio includes:

  • Dermatological medicines
  • Photodynamic therapy
  • Medical technologies for the management of skin diseases
  • Scientific collaborations
  • Support for healthcare professionals, treating a range of dermatological conditions.
  1. January 1997

    Biofrontera founded in Leverkusen, Germany

    Research begins on photodynamic therapy nanoemulsion drug delivery.

  2. January 2006

    Listed on the Frankfurt Stock Exchange

    Biofrontera goes public, funding further clinical development.

  3. January 2011

    Ameluz® receives EU regulatory approval

    From the European Medicines Agency.

  4. January 2016

    Marketing of Ameluz® begins in the UK.

    Biofrontera commences partnership with Spirit Healthcare.

  5. January 2018

    New UK team set up within the Biofrontera group

    To take over the promotion of Ameluz®.

  6. January 2022

    UK affiliate established

    Biofrontera gains a significant presence in the UK.

  7. 2025

    Ovixan® receives UK regulatory approval

    from the Medicines and Health products Regulatory Agency.

  8. 2026

    Ovixan® launched in the UK

    Expanding Biofrontera’s product range in Europe

Scientific,
dermatological
solutions

Biofrontera UK’s portfolio offers prescription medicines and medical technologies for specific dermatological skin conditions.

We support healthcare professionals – from NHS nurses to private doctors and beyond – in the management of skin diseases, in accordance with the licensed indication of each product.

Scientists working in a laboratory
Ameluz 78 mg/g gel box and tube

Ameluz®

78mg/g 5-Aminolaevulinic acid gel

Indication: A prescription-only nanoemulsion gel, treatment of Actinic Keratosis of mild to moderate severity (Olsen grade 1 to 2) and of field cancerization in adults. Treatment of superficial and/or nodular Basal Cell Carcinoma unsuitable for surgical treatment due to possible treatment related morbidity and/or poor cosmetic outcome in adults. Use in accordance with the Summary of Product Characteristics.

For use by HCPs experienced in the use of PDT. Applied topically and activated by calibrated red-light illumination, artificial daylight or natural daylight. Ameluz® forms part of Biofrontera UK’s specialist dermatology portfolio.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Biofrontera Pharma GmbH on +49 214 876 32 66.

View prescribing information
Ovixan 1 mg/g cream tubes

Ovixan®

1mg/g mometasone furoate

Indication: Prescription-only topical corticosteroid, indicated for the treatment of inflammatory and pruritic manifestations of Psoriasis (excluding widespread Plaque Psoriasis) and Atopic Dermatitis, Ovixan® cream forms part of Biofrontera UK’s dermatology portfolio. Ovixan® cream is a potent corticosteroid. Applied once daily, Ovixan® cream should always be used in accordance with the Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Biofrontera Pharma GmbH on +49 214 876 32 66.

View prescribing information
Two healthcare professionals talking together

Providing support for
healthcare professionals

Biofrontera UK assists with the advancement of evidence-based dermatological care, focusing on ongoing collaboration with a range of healthcare professionals.

We support healthcare professionals via:

  • Scientific exchange
  • Medical information
  • Educational materials, initiatives and events
  • The development of our portal for healthcare professionals, which is launching soon.

If you have a general enquiry, please contact the Biofrontera UK team on enquiries-uk@biofrontera.com

We’re busy behind the scenes…

Biofrontera UK is committed to advancing dermatological care through science, advancements and education.

Our brand-new UK website is currently under construction. Please get in touch on enquiries-uk@biofrontera.com for more information.

Email Us